FPT-SOFTWARE/SCSK-EU
Vietnam’s leading Digital Transformation services provider FPT Software has recently unveiled its partnership with SCSK Europe, a subsidiary of the Japan-based system integrator SCSK Corporation. The collaboration affirms FPT Software’s robotic process automation (RPA) expertise and further expands its foothold in the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005262/en/
Applying “Fast Automation” framework, FPT Software has successfully helped SCSK Europe streamline six internal processes by deploying its award-winning RPA platform akaBot in four weeks. The offshore team then provided a comprehensive understanding of RPA’s benefits and armed SCSK employees with the necessary skills and mentality for the upcoming changes with the emergence of digital transformation. Following their internal success, SCSK Europe introduced FPT Software’s akaBot to their clients in the Chemical and Agriculture industries to help replace 100 percent human effort in their data extraction and loan credits approval processes.
"RPA is a powerful tool to resolve the bottleneck in business processes, delivering a much streamlined and efficient workflow. We believe that we can always extend the automation horizons even more by integrating RPA robots with other intelligent technologies,” said Masatoshi Chiba – General Manager, SCSK EU.
“With that expectation in mind, we decided to partner with akaBot, one of the leading vendors in developing hyper-automation solutions from FPT. Since 2018, we have established MOU for the comprehensive partnership to seek to supply a wider range of services and solutions and to expand our operations in the global through this partnership with FPT," Masatoshi Chiba further shared.
According to FPT Software Chief Operating Officer Tran Dang Hoa, the collaboration "paved the way for FPT Software’s expansion in robotic automation and digital transformation in the EU and on a global scale."
"Like SCSK, more and more firms worldwide are adopting RPA and hyper-automation to enhance operations," Tran Dang Hoa said. "As a global top 30 RPA solution provider, we aspire to accompany businesses to overcome pressing challenges, boost their productivity and save costs," he added.
FPT Software and SCSK’s partnership dates back to 2018 when the two cooperated in supporting the overseas expansion of Japanese companies, especially in financial and automotive systems development. Both sides joined forces in providing IT Services and business development through the Asia Pacific operations of major SCSK’s shareholder – Sumitomo Corporation.
First entering the European market in 2008, FPT Software has established seven offices and development centers, and is determined to penetrate further with digital transformation as the key driving force. The global IT firm targeted this strategic area as its first port for capital commitment in the value of 100 million dollars in the upcoming years, with the UK and Germany as two major geographies.
About FPT Software
FPT Software is a global technology and IT services provider headquartered in Vietnam, with USD 632.5 million in revenue and 22,500 employees in 26 countries. As a pioneer in digital transformation, the company delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Cloud, AR/VR, BPO, and more. It has served 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For further information, please visit http://www.fpt-software.com .
About SCSK EU
SCSK Europe Ltd. was established in London in 1990 as a fully-owned subsidiary of SCSK Corporation, one of Japan's leading IT service companies with more than 14,000 employees. We are One Stop IT Service Provider and a proven strategic business partner to Japanese-related corporations operating in EMEA/CIS providing various IT Solutions including RPA. For further information, please visit SCSK Europe Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom